Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs Enphase Energy Inc (ENPH) Price & Performance

BioNTech SE - ADRTrade
Enphase Energy IncTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs Enphase Energy Inc — how do they compare? BioNTech SE - ADR trades at $89.87 (market cap $22.86B), while Enphase Energy Inc trades at $43.43 (market cap $5.93B). The key difference: BioNTech SE - ADR is far larger — about 3.9× Enphase Energy Inc's market cap, and Enphase Energy Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.

BNTXENPH
Market Cap
$22.86B$5.93B
Sector
HealthTechnology
52-Week High
$119.34$72.33
52-Week Low
$83.89$26.12
Enterprise Value
$6.53B$5.58B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.

The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.

Enphase Energy Inc

Enphase Energy (ENPH) trades at $43.06, down 3.95% on the day, near its consensus price target of $42.79. The stock shows a bearish technical signal with declining cash flows and mixed earnings trends, though recent quarters have beaten estimates. Recent news includes product expansions in Australia and New Zealand and involvement in AI data center power standards, providing some positive catalysts amid overall market caution.

Outlook remains cautious with high valuation ratios (P/E 44.39) pressuring upside, while analyst sentiment is divided (40% Buy, 51% Hold). Key risks include competitive pressures and volatile solar demand, but institutional interest and strategic initiatives offer potential for recovery if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About Enphase Energy Inc

Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.

Read more on ENPH